Posted by Michael Wonder on 22 Jan 2025
Abiraterone acetate with niraparib tosylate monohydrate and prednisone for untreated hormone-relapsed metastatic prostate cancer
22 January 2025 - NICE is unable to make a recommendation on the use in the NHS of abiraterone acetate with niraparib tosylate monohydrate for use in combination with prednisone for the treatment of adults with hormone relapsed metastatic prostate cancer.
This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
